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SUMMARY
Malignantmesothelioma (MM) is an aggressive neoplasm characterized by a poor patient survival rate, because of rapid tumor recurrence
following first-line therapy. Cancer stem cells (CSCs) are assumed to be responsible for initiating tumorigenesis and driving relapse
after therapeutic interventions. CSC-enriched MM cell subpopulations were identified by an OCT4/SOX2 reporter approach and were
characterized by (1) increased resistance to cisplatin, (2) increased sensitivity toward the FAK inhibitor VS-6063 in vitro, and (3) a higher
tumor-initiating capacity in vivo in orthotopic xenograft and allograft mouse models. Overexpression of NF2 (neurofibromatosis 2,
merlin), a tumor suppressor often mutated or lost in MM, did not affect proliferation and viability of CSC-enriched MM populations
but robustly decreased the viability of reporter-negative cells. In contrast, downregulation of calretinin strongly decreased proliferation
and viability of both populations. In summary, we have enriched and characterized a small MM cell subpopulation that bears the
expected CSC characteristics.
INTRODUCTION
Malignant mesothelioma (MM) is a highly aggressive
neoplasm most often linked to exposure to asbestos fibers,
which induce chronic inflammation and perpetual tissue
repair by the surrounding mesothelial cells. Chronic hy-
per-proliferation leads to a series of genetic and epigenetic
modifications of these cells gradually developing into ma-
lignant cancer cells and tumor formation (Stahel et al.,
2009). Therapy generally comprises a combination chemo-
therapy consisting of cisplatin (cis-Pt) and pemetrexed, at
times accompanied by radiotherapy and/or tumor removal
by surgery (Cho et al., 2014). The low success rate of treat-
ments is likely caused by a subpopulation of tumor cells
characterized by high resistance to chemotherapy and a
high tumor-forming potential leading to rapid recurrence,
the so-called cancer stem cells (CSCs). Currently no uni-
versal markers exist for unambiguously identifying CSCs
in MM or other cancer types, possibly linked to the dy-
namic and heterogeneous properties of CSCs (Akrap
et al., 2016). Various assays have been described to enrich
CSC-containing tumor cell subpopulations: fluorescence-
activated cell sorting (FACS) of putative CSCs, some-
times also called tumor-initiating cells (TICs), relies mostly
on expression of cell surface markers (CD133, CD44,
CD24; Klonisch et al., 2008; or EpCAM; Visvader and Lin-
deman, 2008) or on dye-exclusion assays based on the
elevated expression of ABC transporter family members,
e.g., ABCG2 (Hirschmann-Jax et al., 2004). Alternatively,
increased aldehyde dehydrogenase (ALDH1) activity char-
acterizes a subpopulation of cancer cells with CSC proper-
ties (D’Angelo and Wicha, 2010), also in human MM cell
lines (Shapiro et al., 2014). The currently most comprehen-
sive characterization of CSC subpopulations has allowed
the identification of a hierarchical organization, where
CSC subpopulations dynamically change between various
differentiation states (clusters) (Akrap et al., 2016). Each
cluster is characterized by a series of genes; CSCs expressing
typical (normal) pluripotency stem cell marker genes such
as SOX2, NANOG, and OCT4 (also named POU5F1) were
found at the apex of the hierarchy, followed by populations
of one to several types of progenitor cell populations
expressing genes such as ALDH1 and ABCG2. Thus, CSC-
enrichment methods based on stem cell marker expression
including SOX2 and OCT4 have been particularly success-
ful in selecting tumor cells with (1) the high tumor-forming
potential in vivo, (2) the particular growth properties
including self-renewal and asymmetric cell division, (3)
the increased chemoresistance, and (4) the aggressiveness
shown in other cancer types (Gangemi et al., 2009; Tang
et al., 2015). The concept that CSCs within a tumor mass
might represent important targets for therapy is now
accepted for nearly all cancer types (Valent et al., 2012).
Here, we identified and characterized MM cell subpopu-
lations in vitro based on their increased endogenous
expression of SOX2 and OCT4 driving a reporter (EGFP)
(Hotta et al., 2009; Tang et al., 2015).We demonstrate these
cells to have different properties with respect to chemore-
sistance, and that the proportion of these cells appears to
be determined intrinsically, also involving asymmetric
cell division. Moreover, overexpression of the tumor
suppressor NF2 caused an almost complete block of cell
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proliferation in non-enriched CSC cells, while high SOX2/
OCT4-expressing cells selected by the reporter approach
were barely affected by forced NF2 expression. Injection
of the EGFP(+) cells resulted in an increased frequency,
number, and size of tumors in vivo compared with cells
with low SOX2/OCT4 expression. These results are indica-
tive of a CSC-enriched population in MM cell lines of hu-
man and mouse origin likely relevant for tumor relapse.
RESULTS
Identification and Initial Characterization of High
SOX2/OCT4-Expressing Human CSC-Enriched MM
Cells
To identify putative CSCs in MM, we relied on a tool
initially developed for stem cell biology (Hotta et al.,
2009). In this lentivirus-based approach, MM cells of hu-
man and mouse origin were infected with a construct that
contains SOX2- andOCT4-binding sites in the promoter re-
gion, followed by an expression cassette coding for EGFP
and an IRES connecting to a puromycin-resistance cassette
(Figure 1A). Thus, cells expressing high levels of SOX2/
OCT4 can be identified by EGFP expression and, moreover,
selected/isolated by their puromycin resistance and/or by
FACS. The overall lentiviral transduction efficiency in
MM cell lines was assessed with a constitutive NLS-
mCherry construct (Figures S1B and S1C). FACS analyses re-
vealed approximately 85%of cells to show redfluorescence;
an overlay of bright field and fluorescence images from
transduced ZL55 and RN5 MM cells and visual inspection
indicated that the transduction efficiency was likely even
higher, i.e., in the order of >90% (Figure S1B). In the popu-
lation of infected ZL55 cells named ZL55-SO cells, we
observed approximately 5% of EGFP-expressing (EGFP(+))
cells (Figure 1B). A similar percentage of high SOX2- and
OCT4-expressing EGFP(+) cells (ZL55 z 4%; Figure S1A3)
was obtained with the SORE6 reporter construct previously
Figure 1. An EGFP Reporter-Based and Pu-
romycin-Selected Subpopulation of ZL55
Cells Shows Higher Transcript Levels of
CSC-Associated Genes
(A) Schematic representation of the pL-SIN-
EOS-S(4+)-EiP lentiviral (LV) construct with
OCT4 (blue) and SOX2 (orange) binding
sites. Binding of OCT4 and SOX2 initiates
expression of EGFP and PuroR.
(B) A small percentage of EGFP(+) cells is
present in LV-transduced ZL55 cells (left
panel, bright field image; right panel, fluo-
rescence image).
(C) FACS analysis reveals an EGFP(+) sub-
population of around 5% (C2); with the same
gating only 0.05% of non-infected ZL55
cells are counted (C1).
(D) Directly after puromycin selection strin-
gent FACS analysis of ZL55-SO-P2 cells iden-
tifies 78.6% of cells as EGFP(+).
(E) PuroR selection results in a visibly 100%
positive EGFP(+) ZL55-SO-P2 subpopulation
(right); left image: bright field image of the
same cells.
(F) qRT-PCR reveals a 4.5-fold increase for
SOX2 expression in ZL55-SO-P2 and ZL55-SO-
P10 cells (selected with 2 or 10 mg/mL of
puromycin, respectively) compared with the
non-selected ZL55-SO cells. OCT4 levels are
increased 1.9-fold in -P2 and nearly 6-fold
in the -P10 cells. A significant increase in
the expression of ABCG2 as well as CSF1R is
detected. Statistical comparisons were per-
formed using a one-way ANOVA (*p < 0.05)
from three independent experiments; error
bars represent SD. See also Figure S1.
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used in breast cancer cells (Tang et al., 2015). This per-
centage lies within a similar range to that observed for
the ZL55 side population (2% SP cells, Frei et al., 2011) or
ALDEFLUOR-positive(+) MM87 cells (3.8%; Shapiro et al.,
2014). Quantitative analyses by FACS showed 4.86% of
ZL55-SO cells to express sufficiently high levels of SOX2
and OCT4 to drive EGFP expression (Figure 1C). ZL55-SO
cells subjected to puromycin (2 mg/mL) selection for
7 days revealed the surviving cell population to show vari-
able EGFP expression andwerenamedZL55-SO-P2. Inorder
to exclude likely EGFP-negative or low EGFP-expressing
cells in the quantitative FACS analyses, based on the strin-
gent FACS settings, 78.6% of ZL55-SO-P2 cells fulfilled the
criteria to be unmistakably identified as EGFP(+) cells (Fig-
ure 1D); yet, by eye, essentially all cells appeared to emit
green fluorescence (Figure 1E). In addition, we generated
ZL55-SO-P10 cells, where the puromycin concentration
was augmented to 10 mg/mL aimed at selecting cells with
the highest levels of SOX2 and OCT4. Expression levels
(mRNA) of SOX2, OCT4, as well as previously proposed
MM CSC markers including ABCG2 and CSF1R, all impli-
cated inmesothelioma chemoresistance,were considerably
increased (on average 3- to 5-fold) in puromycin-selected
ZL55-SO cells (Figure 1F). The largest increase from -P2 to
-P10 cells was observed for OCT4 (Figure 1F). Experiments
were carried out with FACS-sorted cells, which were sepa-
rated based only on their EGFP fluorescence. Details for
the sorting are provided in Figure S2A. The identical
approach was also used to obtain sorted RN5 cells (Fig-
ure S2B). We screened the sorted cells for ALDH1A1, KLF4,
and c-MYC, which were all increased in ZL55-SOhigh cells
(Figures S1D and S1E). In the sorted murine RN5-SOhigh
cells, besides Sox2 and Oct4, the stem cell marker Nanog
was also significantly increased (Figure S1F). A hallmark
for putativeMMandother tumor type-derivedCSCs is their
increased resistance toward chemotherapeutic drugs
including cis-Pt, as also reported previously for ovarian can-
cer-derived CSCs (Wiechert et al., 2016). ZL55-SO and
ZL55-SO-P2 cells were treated with cis-Pt concentrations
ranging from 0.625 to 10 mM, and cell survival was assessed
5 days later (Figure 2A, left panel). Half maximal inhibitory
concentration (IC50) values were 0.92 mM for ZL55-SO and
2.13 mM for ZL55-SO-P2 cells, indicating that the EGFP(+)
cells displayed higher chemoresistance, i.e., higher survival
than the non-selected ZL55-SO cells. While ZL55-SO-P2
cells were almost completely resistant to 1.25 mM cis-Pt as
shown by nearly identical growth curves of cis-Pt-exposed
and untreated cells, the growth/survival of ZL55-SO cells
was considerably impaired under these conditions (Fig-
ure 2C). Of note, in ZL55-SO cells, the cells surviving the
cis-Pt treatment were to a large extent EGFP(+) cells (Fig-
ure 2D) present at about 5% in the non-selected ZL55-SO
cells (Figures 1B and 1C). Also, the sorted ZL55-SOlow and
ZL55-SOhigh cells were exposed to cis-Pt and IC50 values
were determined (Figures 2A and 2B). The increase in sur-
vival of ZL55-SOhigh cells compared with ZL55-SOlow cells
in the presence of cis-Pt was qualitatively similar to that
in the puromycin-selected ZL55-SO-P2 versus ZL55-SO cells
(Figure 2A). With respect to the increased resistance, the
ratio of IC50 values for the EGFP(+)-sorted cells (2.7-fold)
was slightly higher than for the -SO-P2 versus -SO cells
(1.9-fold); the smaller difference in the puromycin-selected
cells likely being due to the presence of approximately 5%
of EGFP(+) cells in the parental (unsorted) -SO cell popula-
tion. Sorted cells were also exposed to 5-fluorouracyl (5-FU)
and to the FAK inhibitorVS-6063, also known as defactinib.
IC50 values are summarized in Figure 2B. Of note, no differ-
ences were detected in ZL55-SOlow and ZL55-SOhigh cells
with respect to their 5-FU sensitivity. In line with previous
observations that FAK signaling is increased and function-
ally relevant in putative CSCs (Shapiro et al., 2014), ZL55-
SOhigh cells weremore susceptible toward the FAK inhibitor
than the ZL55-SOlow cells (Figures 2A and 2B).
SOX2/OCT4-Expressing CSC-EnrichedMMCells Show
Stem Cell Properties In Vitro
An essential property of stem cells is asymmetric cell
division, i.e., the ability to generate two daughter cells
with non-identical properties. We hypothesized that in
ZL55-SO-P2 EGFP(+) cells not continuously subjected to
puromycin selection or in FACS-sorted ZL55-SOhigh cells,
a fraction of cells would eventually lose EGFP expression,
possibly resulting from asymmetric cell division and/or a
dynamic switch in CSC differentiation state (Movie S1).
While 1 day after puromycin removal essentially all cells
were EGFP(+), at later time points (days 6, 71, and 80), first
individual EGFP() cells and at later stages entire cell
clusters of EGFP() cells were observed (Figure 3A and
Movie S2). Asymmetric cell divisions were documented
by time-lapse videos, where mitosis of an EGFP(+) cell re-
sulted in a green and a non-green daughter cell (Movie
S1). A decrease of EGFP(+) cells by 13% was observed at
day 80 (10 passages) (Figure 3B and Movie S2), and green
cells decreased even more after long-term culturing
in vitro (data not shown). Their advancement in differenti-
ation from EGFP(+) to EGFP() cells was confirmed by their
subsequent increased NF2 susceptibility (Movie S4). Of
note, within the population of EGFP(+) cells, a second
population of cells appeared with a weaker green fluores-
cence intensity, close to the gating boundaries separating
EGFP(+) and EGFP() cells (Figure 3B). We conclude that
EGFP expression is not based on an all-or-none mecha-
nism, but it exists rather as a continuum of cells with
different SOX2/OCT4-based reporters as shown by the het-
erogeneous EGFP levels possibly resulting from a switch in
CSC differentiation state.
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SOX2/OCT4-Expressing CSC-Enriched MM Cells Are
Present in Cell Lines Derived from All Human MM
Histotypes and Also in Murine RN5 MM Cells
Patients with sarcomatoid and biphasic MM have a poorer
prognosis than patients diagnosed with an epithelioid MM
(Bille´ et al., 2016). Thus, we set out to investigate whether
high SOX2/OCT4-expressing cells were present in cell lines
derived from all different MM histotypes and to determine
the proportion of EGFP(+) cells. EGFP(+) cell populations
were detected in ZL55 (epithelioid), MSTO-211H, SPC111
(biphasic), and murine RN5 (sarcomatoid) cells; their frac-
tions ranged from 4.8% to 7.8% (Table 1). Thus, in all three
histotype-derived MM cell lines, EGFP(+), CSC-enriched
cell populations were identified. Murine EGFP(+) RN5 cells
were used in a syngeneic orthotopic in vivo mouse model
aimed at demonstrating that the decrease of EGFP(+) cells
observed in culture is not an artifact of in vitro cell culture
conditions and/or specific for a certainMM cell line. Sorted
RN5-SOhigh cells were used in an in vivo allograft C57Bl/6J
mouse model. Intraperitoneal (i.p.) injection of these cells
resulted in tumor nodules after 8 weeks; staining of fixed
tumors with a pan-cytokeratin (CK) antibody allowed
identification of the tumor cells, further confirmed by dou-
ble staining for EGFP (Figure 3C). The tumor contained
patches of cells with strong EGFP expression, but also re-
gions with weak or absent expression, although these cells
were clearly CK positive, i.e., tumor cells. This indicates
that a fraction of EGFP(+) tumor cells had lost SOX2/
OCT4-driven reporter expression over time in vivo.
Furthermore, RN5-SOhigh-sorted cells were transduced
with NLS-mCherry and injected (i.p.) into mice. Tumors
were collected after 8 weeks and isolated tumor cells were
cultured in vitro for analysis. Among the NLS-mCherry-
labeled RN5 MM cells, a fraction of EGFP() cells was de-
tected (marked by arrows; Figure 3D). In addition, these
NLS-mCherry-transduced RN5-SOhigh cells were cultured
in vitro for an additional 57 days. Cells were analyzed
weekly by FACS; the fraction of EGFP() cells increased
Figure 2. Higher Resistance of ZL55-SOhigh EGFP(+) Cells Toward cis-Pt and 5-FU and a Lower One Toward VS-6063
(A and B) Increased viability of ZL55-SO-P2 versus ZL55-SO cells exposed to cis-Pt (left panel) (A). From the curves derived from sorted
ZL55-SOlow and ZL55-SOhigh cells (right three panels), IC50 values for cis-Pt, 5-FU, and VS-6063 were calculated from three independent
experiments and are shown in (B). ***p < 0.001; one-way ANOVA; n.s., not significant. ZL55-SOhigh cells display higher susceptibility to
VS-6063.
(C) Real-time growth curves show the strong effect of cis-Pt (1.25 mM) on ZL55-SO cell proliferation/survival, while ZL55-SO-P2 cells are
almost completely resistant. One representative experiment from three independent experiments.
(D) Bright field and fluorescence images showing the effect of cis-Pt on ZL55-SO cells; the fraction of EGFP(+) cells is increased after cis-Pt
exposure (right panels).
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Figure 3. Time-Dependent Decrease in EGFP Expression in Initially 100% EGFP(+) Cells Indicates Gradual Loss of Stemness
Observed In Vitro and In Vivo
(A) Example of EGFP(+) and EGFP() ZL55-SO cells in a cell culture dish initially plated with FACS-sorted ZL55-SOhigh cells. At 80 days
in vitro many non-green EGFP() cells are observed, often arranged in clusters (marked by yellow dotted lines) and EGFP(+) (examples
marked by red dotted lines).
(B) Decrease of the fraction of EGFP(+) cells starting from sorted ZL55-SOhigh cells (initially 78.6% EGFP(+) cells) to 68.7% after culturing
without puromycin selection for 35 days (ten passages). Note the appearance of a distinct population of cells with lower EGFP fluorescence
(arrow).
(C) Tumor tissue derived from a mouse injected with RN5-SOhigh cells for 8 weeks in vivo. In the tumor mass identified by pan-cytokeratin
(CK) immunohistochemistry (red fluorescence), clusters of cells with weak-to-none EGFP staining (green fluorescent image; left) are seen.
Staining with DAPI (blue) allows better identification of individual cells. In the merged image, the presence of clusters of yellow cells (co-
localization of CK and EGFP), but also of cells without EGFP (CK only) demonstrates loss of EGFP expression over time in vivo.
(D) RN5-SOhigh cells additionally expressing NLS-mCherry (red fluorescent nuclei) formed tumors in vivo as demonstrated after 8 weeks.
Tumor-derived cells were cultivated in vitro and revealed that a fraction of NLS-mCherry(+) cells had lost EGFP expression (cells marked by
arrows). In the merged image these cells appear as red only.
(legend continued on next page)
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from 0.4% to 22.2% after 57 days, while the fraction of
NLS-mCherry() cells only decreased by 0.8% in the
same time period (Figure 3E). An overlay of the green and
red cell populations present in cell cultures after 57 days
in vitro revealed a left shift of the green cells toward lower
fluorescence (increase in EGFP() cells), while at the same
time the cluster of red cells did not move (Figure 3E). This
indicates a selective decrease of EGFP(+) cells over time,
i.e., SOX2/OCT4 levels had dropped below the threshold
to maintain EGFP expression.
Tumor Growth of ZL55-SOhigh Cells In Vivo Strongly
Indicates CSC Properties
The growth of FACS-sorted ZL55-SOlow and ZL55-SOhigh
cells was investigated in vivo in an orthotopic xeno-
graft mouse model. Non-obese diabetic (NOD)/severe
combined immunodeficiency (SCID) gamma mice were
injected i.p. with 100,000 of either sorted ZL55-SOlow
or ZL55-SOhigh cells and the formation of tumor nodules
was analyzed 5 weeks after injection. All mice exposed to
either cell subpopulation showed macroscopic tumor
formations on both the parietal and visceral part of
the tunica serosa (Figure 4A). We measured semi-quanti-
tatively the relative surface area covered by tumor tis-
sue; a clearly larger surface area covered by visually
discernible tumor nodules after injection of ZL55-SOhigh
cells was observed (Figure 4B). In some cases nearly the
entire parietal tunica serosa of mice injected with ZL55-
SOhigh cells was covered with tumor nodules, but to a
lesser extent also the visceral tunica serosa of different
organs was covered (Figure 4A). The semi-quantitative
analyses showed that the tumor-initiating capacity of
ZL55-SOhigh EGFP(+) cells was clearly higher than that
of ZL55-SOlow EGFP() cells. Histological analyses of
selected ZL55-SOhigh tumor nodules showed irregularly
formed boundaries between liver tissue and tumor
mass, indicative of a highly invasive tumor (Figure 4C).
Characteristics of RN5-SOhigh Tumor Cell Growth
InVivoAreDifferent from theOne after Injectionwith
RN5-SOlow Cells
A limited dilution assay was carried out, where different
amounts of FACS-sorted murine MM cells (RN5-SOhigh
and RN5-SOlow; 5,000, 50,000, and 500,000 cells per
mouse) were injected i.p. in syngeneic C57Bl/6J mice. At
three time points 13, 11, and 8 weeks post injection,
mice with the largest initial load analyzed after the shortest
period were killed and the tumor load/tumor size was
investigated semi-quantitatively, first at the macroscopic
level and then in more detail on histological sections (Fig-
ure 5). Injection of EGFP() RN5-SOlow cells resulted in the
formation of macroscopically discernable tumors in 1 of
12 mice (8.3%); the tumor localization was intramuscular
(Figure 5C). More tumors (in 6 of 12 mice; 50%) were
detected after injection of RN5-SOhigh cells; an example
of an externally visible tumor of RN5-SOhigh cells is
shown in Figure 5B. Histological analyses revealed that
RN5-SOhigh-derived tumors often localized within the sub-
cutaneous connective tissue, in intramuscular regions of
the abdominal wall, but also on the kidney capsule (Fig-
ures 5D–5G). Different tissue samples containing small tu-
mormasses frommice injected with either RN5-SOhigh and
RN5-SOlow cells were histologically examined. In the RN5-
SOlow group, tumors were identified in 4 of 12 (33%) mice
and clearly more (9 of 12 mice; 75%) in mice injected with
RN5-SOhigh cells (Figure 5A). The tumor incidence in RN5-
SOhigh-injected mice was higher at all three doses of tumor
cells tested (Figure 5A). The calculated tumor-initiating fre-
quency using the ELDA software (Hu and Smyth, 2009) for
RN5-SOhigh cells was clearly higher than for RN5-SOlow
cells (ratio RN5-SOhigh/RN5-SOlow, 17.4; p = 0.0063).
Thus, also in vivo, EGFP(+) RN5-SOhigh cells fulfill the
criteria of CSC-enriched cells shown by their increased tu-
mor-initiating frequency.
Increased In Vitro Self-Renewal Properties of RN5-
SOhigh and ZL55-SOhigh Cells Compared with the
Corresponding -SOlow Subpopulations
Other importantCSC characteristics include an augmented
capacity for self-renewal and also for anchorage-indepen-
dent growth in vitro (Morata-Tarifa et al., 2016). Self-
renewal was assessed in ZL55 and RN5 cells by a limiting
dilution assay as described previously (Tang et al., 2015;
Thiagarajan et al., 2015) using sorted -SOlow and -SOhigh
cells of both cell types. In both cell lines, the self-renewal ca-
pacity of EGFP(+) cells was clearly increased (Figures S3A
(E) Cells shown in (D) were maintained in culture in vitro for an additional 57 days and analyzed by FACS for green (EGFP) and red (NLS-
mCherry) fluorescence. While the fraction of NLS-mCherry(+) cells only marginally decreased from 99.8% to 99.0%, the fraction of EGFP(+)
cells decreased from 99.6% to 77.8%. Note the left shift of the population of EGFP(+) cells: blue cloud at t1; red cloud at t57. See also
Figure S2.
Table 1. Percentage of EGFP(+) Cell Populations in Human and
Mouse MM Cell Lines
Cell Line Origin/Characterization % GFP(+) Cells
ZL55 human/epithelioid 4.8
SPC111 human/biphasic 6.2
MSTO-211H human/biphasic 6.1
RN5 murine/sarcomatoid 7.8
1010 Stem Cell Reports j Vol. 8 j 1005–1017 j April 11, 2017
and S3B). Examples of EGFP() and EGFP(+) RN5 tumor
spheres initiated from 10 cells/well and maintained in cul-
ture for 10 days are shown in Figures S3C and S3D, respec-
tively; the larger size of EGFP(+) tumor spheres was evident.
In addition, the anchorage-independent growth in soft agar
was investigated in the same cell lines. The average colony
size of EGFP(+) RN5-SOhigh cells after 2 weeks (Figure S3E)
was considerably larger than the size of the corresponding
EGFP() RN5-SOlow colonies (Figure S3F). Assuming a
spherical shapeof thecolonies, basedon theareasof thecol-
onies depicted in Figures S3E and S3F, the radius of a sphere
was calculated. Theaverage radiuswas significantly larger in
RN5-SOhigh cells than in the RN5-SOlow cells (Figure S3H).
The differences in radii were smaller between EGFP()
and EGFP(+) ZL55 cell colonies; however, radii of ZL55-
SOhigh cell colonies were still significantly larger than the
ones from EGFP() cells (Figure S3G).
Decreased Susceptibility of EGFP(+) ZL55 Cells to
Asbestos-Induced Acute Cytotoxicity, but Unaltered
Cell Mobility In Vitro
CSCs are known to show higher resistance to exposure to
cytotoxic agents (Vidal et al., 2013), possibly linked to their
lower proliferation rates,while increased spreadingof tumor
cells to sites distant from the primary tumor are associated
with augmented invasiveness and increased metastatic
potential (Anjomshoaa et al., 2009). ZL55-SO-P2 EGFP(+)
cells were significantly more resistant toward crocidolite-
induced acute cytotoxicity (5 mg/cm2 of crocidolite for
96hr) thanEGFP() cells (Figure6A).At96hr theMTTsignal
of ZL55-SO-P2 crocidolite-treated cells was only slightly
lower than in control ZL55-SO-P2 cells, indicating an almost
complete protection of EGFP(+) cells. Real-time growth
curves of control ZL55-SO and ZL55-SO-P2 cells did not
reveal large differences in the proliferation rates of the two
cell populations (Figures 6C and 6D). The MTT signal at
120hrpost-plating forEGFP() ZL55-SOlow cellswas slightly
larger than for EGFP(+) ZL55-SOhigh cells, in linewith slower
growth of CSCs (data not shown). Yet in a 2D scratch assay,
the wound closure time was indistinguishable (data not
shown). A more detailed analysis of the mobility of indivi-
dual cells preferentially toward the cell-devoid area showed
a faster cell movement of both cell groups directly following
the scratch and lasting for about 2 hr, followed by a constant
displacement of approximately 2 mm/5 min for the next
16 hr (Figure S4C). Mobility of ZL55-SO cells grown at low
confluence, i.e., allowing for non-directed movement was
also not different between EGFP(+) and EGFP() cells (Fig-
ure S4C). In addition, we used MSTO-211H cells, an MM
cell line prone to form spheroidswhen grown in the absence
of serum, to analyze the spheroid formation capacity (Pasdar
et al., 2015). MSTO-211H-SO-P2 cells consisting of mostly
EGFP(+) cells showed qualitatively a larger number of spher-
oids (data not shown) that were also bigger than the
ones from unsorted MSTO-211H-SO cells (Figures S4A and
S4B). Of note, spheroids produced from unsorted MSTO-
211H-SO cells containing initially 7% of EGFP(+) cells
weremostlymadeupof theEGFP(+) cell subpopulation, sug-
gesting that mostly EGFP(+) cells show the propensity of
forming spheroids (Figure S4A).
Similar Sensitivity of EGFP(+) and EGFP() MM Cells
to Calretinin Downregulation, but Pronounced
Differences with Respect to Ectopic Expression of the
Functional Tumor Suppressor NF2 and to the FAK
Inhibitor VS-6063
Although the precise role of the positive MMmarker calre-
tinin (CALB2) is currently unknown, its downregulation
Figure 4. Increased Tumor Growth of Human ZL55-SOhigh
EGFP(+) Cells in NOD/SCID Gamma Mice
(A) ZL55-SOlow and ZL55-SOhigh cells (100,000/mouse) were in-
jected i.p. into NOD/SCID gamma mice. Mice injected with ZL55-
SOhigh cells show an increased number/density of tumor nodules,
especially visible on the visceral pleura (right images).
(B) The percentage of tumor nodules covering the surface of the
visible parietal and visceral peritoneum is 9.1% for ZL55-SOlow cells
and 27.8% for ZL55-SOhigh cells (***p < 0.001; one-way ANOVA).
Average of four to five animals per group; error bars represent SD.
(C) Tumormasseswere histologically analyzed; a tumornodule on the
liver surface shows highly invasive edges (arrow). See also Figure S3.
Stem Cell Reports j Vol. 8 j 1005–1017 j April 11, 2017 1011
in ZL55 cells by a lentivirus-mediated short hairpin
RNA (shRNA) approach leads to massive apoptosis and
necrosis, most strongly in epithelioid MM (Blum and
Schwaller, 2013). Of note, calretinin protein levels were
similar in ZL55-SO and ZL55-SO-P2 cells (Figure 6G) and,
more importantly, downregulation with shCALB2 no. 5,
shCALB2 no. 7 (Blum and Schwaller, 2013), and very effi-
ciently with shCALB2 no. 84 (targeting the CALB2 30
UTR) affected the survival of ZL55-SO and ZL55-SO-P2 cells
to a similar extent (Figure 6B). Thus, unlike the situation
with the FAK inhibitor VS-4718 that preferentially affects
ALDEFLUOR(+), CSC-enriched MM cells (Shapiro et al.,
2014), CALB2 downregulation equally affected prolifera-
tion and viability of ZL55 EGFP(+) and EGFP() cells. These
results underscore calretinin as an interesting target for the
elimination of calretinin-positive MM cells irrespective of
their stemness.
Genes that are downregulated or lost in MM and are
thought to act as a driver for MM formation include NF2
(neurofibromatosis 2, merlin), CDKN2A, and BAP1 (Xu
et al., 2014). Loss of functional NF2 resulting from muta-
tions is observed in 40%–50% of human MPM (Bianchi
et al., 1995) and, moreover, low NF2-expressing MPM cells
show a higher sensitivity toward FAK inhibition-induced
growth arrest, while NF2 overexpression results in an
increased resistance to the FAK inhibitor VS-4718 that
preferentially affects ALDEFLUOR(+) CSC-enriched cells
(Shapiro et al., 2014). Thus, we investigated how overex-
pression of human wild-type NF2 affected proliferation
and/or survival of EGFP(+) and EGFP() MM cells. The pro-
liferation of control ZL55-SO and ZL55-SO-P2 was rather
similar, a plateau was reached between 70 and 80 hr
after plating (Figures 6C and 6D). Overexpression of NF2
(Figures 6C–6F) selectively affected EGFP() ZL55-SO cells,
as shown by an almost complete cell growth arrest and cell
death (Figures 6C–6F). NF2-overexpressing EGFP(+) ZL55
cells showed the typical epithelioid morphology, while
neighboring EGFP() cells were characterized by rounding
up and cell protrusions typical for dying (apoptotic/
necrotic) cells (Figures 6E and 6F; Movies S3 and S4). NF2
upregulation only marginally affected the proliferation
of EGFP(+) ZL55-SO-P2 cells (Figure 6D), and the cell
Figure 5. Increased Tumor-Initiating Fre-
quency and Morphological Aspects of
RN5-SOhigh EGFP(+) Cell-Derived Tumors
in Syngeneic C57Bl/6J Mice
RN5-SOlow and RN5-SOhigh cells were injected
i.p. in C57Bl/6J mice at three doses
(500,000, 50,000, and 5,000 cells) and killed
after 8, 11, and 13 weeks, respectively.
(A) Fraction of mice with tumors found by
microscopic analyses. At all injected doses of
RN5 cells and time points, tumor incidence is
higher with RN5-SOhigh cells. The tumor-
initiating frequency (TIF) was calculated for
both groups.
(B–F) H&E-stained sections. (B) Tumor of
RN5-SOhigh cells (500,000 cells at 8 weeks);
tumor cells are located subcutaneously in
the parietal wall. (C) Intramuscular tumor
in the abdominal wall of the same mouse. (D)
In the same group (500,000 cells at 8 weeks),
tumor cell growth on the liver surface. (E)
and (F) Intramuscular tumors in a mouse
(50,000 RN5-SOhigh cells at 8 weeks).
(G) A parallel section of the one presented
in (F) shows a Goldner staining to better
emphasize the muscle tissue (red) and the
connective tissue (green) in the tumor mass.
Arrows in (F) and (G) indicate muscle fibers.
See also Figure S3.
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morphology was unaltered (Figures 6E and 6F). Nearly
identical results were obtained with human MSTO-211H,
SPC111, and ZL5 cells (Figures S4E–S4J). The slow and de-
layed increase in the proliferation of ZL55-SO-NF2 cells
was the result of the low percentage (5%) of EGFP(+) cells
present in the unselected (-SO) cells, since nearly all
cells were green at 120 hr (Figure S4F). A similar effect
was also seen with murine RN5 cells. The smaller magni-
tude of the effect might be linked to the fact that human,
not mouse NF2, was overexpressed in the mouse cells.
Thus, in line with previous reports demonstrating that
NF2 upregulation in MM cells leads to growth inhibition
and apoptosis (Xiao et al., 2005), NF2 overexpression
blocked proliferation only in -SO cells mostly consisting
of EGFP() cells, while barely affecting EGFP(+) cells.
Thus, in contrast to the EGFP() cells, the CSC-enriched
population derived from all MM histotypes was rather
insensitive to NF2 overexpression. On the other hand,
the FAK inhibitor VS-6063 more efficiently decreased cell
proliferation in ZL55-SO-P2 EGFP(+) cells compared with
ZL55-SO cells (Figures 2A and 2B).
DISCUSSION
MM are exceptionally resistant to therapeutic inter-
ventions such as chemotherapy, radiotherapy, surgery,
and combinations thereof. In many instances therapy
resistance is linked to a particular microenvironment
(Klemm and Joyce, 2015) created and maintained by the
tumor tissue and, moreover, by the heterogeneity of the tu-
mor cells within the tumor mass (Bedard et al., 2013). A
small subpopulation of cancer cells with stem cell features
termed CSCs, or functionally defined as TICs, is assumed
to play a crucial role in the development of cancer and
in promoting its sustained growth and the invasive and
Figure 6. Decreased Susceptibility of
EGFP(+) ZL55 Cells to Asbestos Toxicity
and NF2 Expression; Equal Sensitivity of
EGFP(+) and EGFP() ZL55 Cells to Calre-
tinin Downregulation
(A) Increased resistance of ZL55-SO-P2
cells exposed to 5 mg/cm2 of crocidolite
for 96 hr determined by an MTT assay
compared with ZL55-SO cells (n = 3 inde-
pendent experiments, one-way ANOVA;
***p < 0.0005).
(B–D) Downregulation of calretinin in ZL55-
SO and ZL55-SO-P2 cells equally decreases
the viability in both cell populations for
three different shRNA targeting CALB2 (B)
(n = 3 independent experiments; one-way
ANOVA; n.s., not significant). Overexpression
of merlin (NF2) in ZL55-SO (C) and ZL55-SO-
P2 cells (D) shows strong proliferation-in-
hibiting effects on the non-sorted ZL55-SO
cells, but almost no effect on ZL55-SO-P2
cells. The inset in (D) shows strong upregu-
lation of full-length NF2 (Mr = 68 kDa) us-
ing LV-NF2. All error bars represent SD.
(E) Live-cell imaging of ZL55-SO 3 hr after
upregulation of NF2; note the presence of
EGFP(+) and EGFP() cells in the ZL55-SO
cell population. The morphology of green and
non-green cells is mostly epithelioid.
(F) Twenty-seven hours post infection,
the upregulation of NF2 induced strong
apoptosis/necrosis in non-green cells (white arrows) demonstrated by cell shrinkage, blebbing, and cell debris. EGFP(+) cells do not show
striking morphological changes.
(G) Western blot analysis showing strong downregulation of CR (Mr = 31 kDa) by shRNA CALB2 no. 5 in ZL55-SO and ZL55-SO-P2 cells. At
approximately 35 kDa, the nitrocellulose membrane was cut and the upper part was used for GAPDH detection (lower panel). Control
infection with shRNA GFP has no effect on CR expression. For the normalization the signal for GAPDH (Mr 38 kDa) was used. See also
Figure S4.
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metastatic properties (Raggi et al., 2015). Evidence has
accumulated that these CSCs are characterized by higher
levels of pluripotency factors including SOX2, OCT4, and
NANOG. Based on this, methods have been developed to
isolate this cell subpopulation as applied in our study.
Other approaches to isolate/enrich CSCs exploit specific
properties such as enhanced levels of dye-exclusion
transporters (ABCG2), increased aldehyde dehydrogenase
activity (ALDH1), or their increased propensity to generate
spheroids (Pasdar et al., 2015). While the latter methods
might modify these cells to some extent by the selec-
tion method, the SOX2/OCT4 reporter approach mini-
mally perturbs the endogenous intracellular environment
(excluding the putative effects exerted by EGFP); it allows
the identification and isolation of putative CSCs based
on their endogenously elevated levels of SOX2/OCT4.
Higher levels of SOX2 in glioblastoma were linked with
an increased tumor-initiating ability (Gangemi et al.,
2009), in ovarian carcinoma associated with the stem cell
state, and, in lung cancer, CSCs were required for growth
and metastatic potential (Xiang et al., 2011). Moreover,
elevated levels of OCT4 and other stemness markers in
MM cells derived from mesospheres were paralleled by an
increased tumor-initiating capacity (Pasdar et al., 2015). Re-
porter approaches based on pluripotency factor binding
have been successfully used for the enrichment and identi-
fication of CSCs in breast cancer (Tang et al., 2015; Thiagar-
ajan et al., 2015) and ovarian cancer (Wiechert et al., 2016),
the latter using a NANOG-based reporter. Strong EGFP
expression in the lentivirus-mediated SOX2/OCT4-based
reporter approach allowed us to isolate and characterize
MM cells in vitro and furthermore to investigate in detail
the properties of these cells in vivo. One of themain advan-
tages of the reporter approach is the possibility of continu-
ously monitoring these cells over time. This revealed that a
fraction of initially EGFP(+) cells lost their green fluores-
cence, likely as the result of a decrease in SOX2/OCT4 levels
insufficient to drive EGFP expression; time-lapse movies
demonstrated this loss to occur often within one cell
division. We attribute this to a dynamic shift in the differ-
entiation state from EGFP(+) to EGFP() cells, the latter
characterized by a more non-CSC phenotype as described
in detail for breast cancer CSCs (see Figure 7D in Akrap
et al., 2016). In agreement, the newly formed EGFP() cells
were again equally susceptible to the anti-proliferative/
pro-apoptotic action of elevated levels of NF2 as were the
parental -SO EGFP() cells. This precludes the loss of
EGFP being the result of, e.g., reporter silencing. This
conclusion is also supported by the finding that the same
MM cells constitutively expressing NLS-mCherry did not
lose red fluorescence over time.
MM are considered as an example, where tumorigenesis
is mostly driven by loss of tumor suppressor functions
including genes such as NF2 coding for merlin, CDKN2A,
CDKN2B, or BAP1 (Jean and Jaurand, 2015). Accord-
ingly, NF2 is mutated in approximately 40% of all human
MM (Bianchi et al., 1995) and/or completely absent by
allelic loss (Cheng et al., 1999). NF2 expression levels are
strongly correlated with the sensitivity to inhibitors of
FAK phosphorylation (Shapiro et al., 2014). The FAK inhib-
itor VS-4718 efficiently inhibits proliferation of NF2()
MM cells, while NF2(+) cells are rather insensitive to the
inhibitor.
In our study, we compared the sensitivity of EGFP(+) and
EGFP() MM cells with the effects of overexpression of
NF2. In human NF2-overexpressing MM -SO cells, prolifer-
ation was almost completely blocked, while EGFP(+) CSC-
enriched MM cell populations were barely affected by
increased NF2 levels. This effect was completely indepen-
dent from the NF2 status of the parental cells. NF2-nega-
tive ZL55 cells were equally affected, as were NF2-positive
MSTO-211H cells. The apparently weaker effect in MSTO-
211H-SO cells seen in the real-time growth curves (Fig-
ure S4J) is essentially the result of the insensitivity of the
small subpopulation of EGFP(+) MSTO-211H-SO cells to
NF2 overexpression. Adenovirus-mediated expression of
NF2 was previously shown to inhibit proliferation and to
cause a G1 cell-cycle arrest in NF2-deficient tumor cells
(Xiao et al., 2005). Detailed analyses of NF2-overexpressing
ZL55-SO mostly comprising EGFP() cells revealed not
only a proliferation-inhibiting effect, but considerable
cell death caused by elevated NF2 levels. Inhibition of
FAK signaling by VS-6063 preferentially affected EGFP(+)
ZL55 cells, indicating that a direct impairment of FAK
signaling in CSC-enriched ZL55 cells might be the more
promising strategy than the likely indirect effect on FAK
signaling inhibition by NF2 upregulation that mostly
affected the EGFP() ZL55 cells.
Since downregulation of calretinin decreases the viability
and proliferation of MM cells in vitro (Blum and Schwaller,
2013), we investigated the effects of decreasing calretinin
expression in EGFP(+) and EGFP() cells. Interestingly,
shRNA CALB2-mediated downregulation equally affected
both cell populations with respect to proliferation and
cell death. Thus, calretinin remains an interesting target
to eradicate both MM CSCs and non-CSCs.
The limited dilution assay remains the gold standard for
the identification and characterization of CSC- or TIC-
enriched cell populations. Here we have chosen two ortho-
topic i.p. models presuming that tumor cells encounter an
environment that is more relevant with respect to human
MM pathology (a lumen covered by the mesothelium)
than in the more often used subcutaneous models (Pasdar
et al., 2015; Shapiro et al., 2014). In the xenograft model
using human ZL55 cells, formation of tumor nodules
covering the parietal as well as the visceral mesothelium
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was clearly increased when injecting EGFP(+) cells in
comparison with injection-treated with unsorted ZL55,
comprising less than 5% of EGFP(+) cells. In the physiolog-
ically more relevant allograft model using C57BL/6J mice
characterized by their highly competent immune system
and the previously established mouse MM cell line RN5
(Blum et al., 2015), the tumor-initiating capacity of
EGFP(+) RN5 cells was almost 20-fold higher than that of
EGFP() RN5 cells. Of note, the initial tumor cell load to
induce i.p. tumor nodules with RN5 cells was significantly
higher than the number ofmouseMM87 cells that were in-
jected subcutaneously (s.c.) in the NOD/SCID mouse
model (Shapiro et al., 2014). To summarize, both normal
(C57BL/6J) versus compromised (NOD/SCID) immune sys-
tem cells, and orthotopic versus s.c. injection cells, might
contribute to the higher tumor cell (RN5) load required
for MM formation in vivo.
In comparison with CSCs from tumors derived from
other tissues, the nature of MM CSCs with respect to
niche, interactions with the microenvironment, and
most importantly the immune system and other proper-
ties in vivo are as yet under exploited. We estimate that
the EGFP-based approach will allow also to visualize
EGFP(+) cell fate in the intact tumor microenvironment
in the pleural or peritoneal cavities, e.g., for detailed lon-
gitudinal studies in vivo. In most previous studies, e.g.,
involvement of SOX2 in self-renewal (Arnold et al.,
2011) or tumor-initiating capability (Gangemi et al.,
2009) and the role of OCT4 in dedifferentiation and
stemness of cancer cells (Kumar et al., 2012) has been
investigated separately. Finally, we propose that the
same approach might be applied for primary (non-trans-
formed) mesothelial cells. Such studies might shed light
on the role of normal mesothelial stem cells in the pro-
cess of transformation to MM. The insights into MM
CSC biology provided here are expected to be relevant
in the search for innovative approaches to target this crit-
ically important MM cell population.
EXPERIMENTAL PROCEDURES
Cell Culture and Selection of SOX2/OCT4-Expressing
Cells
MM cell lines were cultured as described above, transduced with
lentivirus containing SOX2/OCT4 stemness indicator constructs
(for details, see the Supplemental Experimental Procedures) result-
ing in ‘‘MM-SO’’ cells consisting of EGFP(+) and EGFP() subpop-
ulations. Treatment with either 2 or 10 mg/mL of puromycin for
10 days led to an enrichment of EGFP(+) cells. In some experi-
ments, ZL55-SO cells were exposed to 2 or 10 mg/mL of puromycin
for 3 weeks, followed by a growth period of 3 weeks (10 passages)
without puromycin. Cells were then analyzed by flow cytometry
for EGFP expression.
Flow Cytometry Analysis of EGFP(+) Cells
Trypsinized MM cells were analyzed by FACS on a BD Accuri C6
(BD Biosciences); details are described in the Supplemental Exper-
imental Procedures. Sorting of EGFP(+) and EGFP() cells was
performed on a BD FACSAria (BD Biosciences) cell sorter and
selected cells were used for subsequent cell culture experiments
in vitro.
Determination of the mRNA Expression of Stemness
Gene Levels by qRT-PCR
Total RNA extracted from 80% confluent cell cultures (peqGOLD
TriFast) of puromycin-selected or sorted ZL55-SO or RN5-SO
cells was used for qRT-PCR following the manufacturer’s instruc-
tions (QIAGEN). qRT-PCR primer sequences are listed in the Sup-
plemental Experimental Procedures.
Treatment of Cells with cis-Pt, 5-FU, and VS-6063 and
Determination of IC50 Values
Cells (500/well for cis-Pt and 5-FU experiments and 2,000/well
for VS-6063) were seeded in 96-well plates and grown for 24 hr.
Drugs were added at different concentrations (for details, see the
Supplemental Experimental Procedures) and the MTT assay was
performed at 48, 96, or 120 hr post treatment (depending on the
drug) to determine IC50 values. Additionally, real-time cell-prolifer-
ation curves were acquired with the IncuCyte Live-Cell Imaging
System (Essen BioScience).
In Vivo Limiting Dilution Assay
Animal experiments were performed with the permission of the
local animal care committee (Canton of Fribourg, Switzerland)
and according to the present Swiss law and the European Com-
munities Council Directive of 24 November 1986 (86/609/EEC).
Murine RN5-SOlow and RN5-SOhigh cells were resuspended in
200 mL PBS and injected i.p. in C57Bl/6J mice (four mice per
group, three different concentrations). Cells (5,000, 50,000, and
500,000) were injected and groups killed in parallel after 13,
11, and 8 weeks, respectively. Photographs were taken to show
macroscopic tumor appearance. Organ samples were collected
(diaphragm, spleen, liver, and peritoneal wall) for histological
analysis. Sorted ZL55-SOlow and ZL55-SOhigh cells (100,000/
mouse) were injected into NOD/SCID gamma mice (four to five
mice per group).
Western Blot Assays for Calretinin, NF2, and
Mesothelin
Proteins were extracted from washed cell pellets (from 70% to
90% confluent cultures) using standard RIPA buffer (for details,
see the Supplemental Experimental Procedures). From the
cleared supernatant, proteins (50 mg) were separated on 10%
polyacrylamide SDS gels and transferred onto nitrocellulose
membranes. After blocking, membranes were first incubated
with antibodies against calretinin, mesothelin, or NF2, followed
by the ABC detection system using the horseradish peroxi-
dase substrate (Millipore, Luminata Forte); membranes were
imaged on the western blot reader FluorChem E System (Bucher
Biotec).
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Downregulation of Calretinin in ZL55-SO and ZL55-
SO-P2 Using Lentiviral-Mediated CALB2 shRNA and
Upregulation of NF2
Cells (500/well in 96-well plates) were grown for 24 hr and trans-
duced with lentivirus shRNA CALB2 nos. 5 and 7 (Blum and
Schwaller, 2013) or a novel 30 UTR-targeted shRNA CALB2:
50-CCG GTT TAA CGC GAT CTT CAC ATT TCT CGA GAA ATG
TGA AGA TCG CGT TAA ATT TTT TG-30. MTT assays were per-
formed at 120 hr post infection. For NF2 upregulation, cells were
transduced with LV-NF2 and growth curves were determined by
the IncuCyte system.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and four movies and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
02.005.
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